Login to Your Account

CRL for Gaucher's Drug; More Expenses Ahead for Protalix

By Tom Wall

Monday, February 28, 2011
On the one hand, Protalix BioTherapeutics Inc.'s president and CEO, David Aviezer, sounded like he was really trying to roll with an FDA complete response letter (CRL) for lead compound taliglucerase alfa in Gaucher's disease that instantly sliced more than 20 percent off the company's stock price and added more costly months to the approval process.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription